MK 7622

Drug Profile

MK 7622

Alternative Names: MK-7622

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class 3-ring heterocyclic compounds; Antidementias; Pyridines; Quinazolinones; Small molecules
  • Mechanism of Action Muscarinic M1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 18 Apr 2016 Merck terminates a phase IIa/IIb trial for Alzheimer's disease (Adjunctive treatment) in USA and Canada (NCT01852110)
  • 24 Dec 2015 MK 7622 is still in phase II trials for Alzheimer's disease (Adjunctive treatment) in USA
  • 24 Dec 2015 Phase-II clinical trials in Alzheimer's disease (Adjunctive treatment) in Canada (PO) (NCT01852110)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top